Biotech News

Pulse Biosciences Strengthens Executive Leadership Team

Pulse Biosciences (PLSE)Pulse Biosciences2026-04-09 11:00 ESTCompany update

Appoints Liane Teplitsky as Chief Operating Officer Expands Dr. David Kenigsberg’s Chief Medical Officer Role HAYWARD, Calif. --(BUSINESS WIRE)--Apr. 9, 2026-- Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy,

Open original release

Pulse Biosciences

Pulse Biosciences is a medical technology company focused on nano-pulse stimulation and nonthermal cellular treatments. Its platform is intended to create new ways to treat tissue while preserving surrounding structures.

Recent company news

PLSEPulse Biosciences2026-05-27 20:05 EST

Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026

Stock data

Close: 32.79 USD
Market cap: 1.68B USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States

Pulse Biosciences Strengthens Executive Leadership Team

Related news

Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026

ATM Equity Purchases by Pulse Biosciences’ Co-Chairmen Total Approximately $13.3 Million

Integra LifeSciences Announces Leadership Transition

Outset Medical Names Derick Elliott as Executive Vice President of Commercial

Sotera Health Announces Leadership Transition